SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RAJU EASON who wrote ()12/10/1998 3:42:00 PM
From: Joseph Ziebarth  Read Replies (1) of 670
 
Qtr. Report ... I have today received the 3rd Qtr. Most telling is the note stating that the Nasdaq has given ProCyte until Dec. 26th to bring the price per share into compliance.

(A reverse split will really hurt this stock right at a time they may begin to show a profit.)

Product sales are up, but the bottom line is an $0.08 loss for the qtr. ProCyte is moving in the right direction to recover, but time is really short.

A 10 for one reverse will bring the price to above $5 / share and drop the number of shares to 1,446,868. My experience has been that after a reverse split the stock slowly degrades down to nothing.

Anyone have a more optimistic view? Sure like to hear one.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext